Inhaled corticosteroids and mortality in COPD [1]

Thorax

Volumn 61, Issue 10, 2006, Pages 918-

  Sin, D D ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO;

CARCINOGENESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DRUG EFFICACY; DRUG MECHANISM; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG FUNCTION; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; INHALATIONAL DRUG ADMINISTRATION; NOTE; DISEASE EXACERBATION; HEALTH STATUS; HOSPITAL ADMISSION; PULMONARY REHABILITATION; QUALITY OF LIFE; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33750032334     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Ernst P, Suissa S. Inhaled corticosteroids and mortality in COPD. Thorax 2006;61:735.
2. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-7.
3. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14. 5-year mortality: a randomized clinical trial, Ann Intern Med 2005;142:233-9.
4. Smyth ET, Wright SC, Evans AE, et al. Death from airways obstruction: accuracy of certification in Northern Ireland. Thorax 1996;51:293-7.
5. Lam S, leRiche JC, McWilliams A, et al. A randomized phase lib trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004;10:6502-11.
6. Yao R, Wang Y, Lemon WJ, et al. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene 2004;23:7746-52.